Women’s health innovation is experiencing a period of rapid growth. Founders are developing new diagnostics, medical devices, digital platforms, wearables and therapies for conditions that have historically received too little research attention and investment.
That opportunity is significant, but bringing a promising idea to patients requires more than identifying an unmet need or building an attractive prototype. Commercialisation needs to begin much earlier than many founders expect.
A product can be scientifically interesting and still fail because it does not solve a sufficiently important problem, cannot be manufactured consistently, lacks a clear regulatory pathway or reaches the market without a sustainable business model.
In women’s health innovation, where many products address sensitive, complex and highly personal experiences, these challenges require careful planning from the beginning.
Start with the problem, not the product
Many companies begin with a technology and then search for a market. A stronger approach begins with a clearly defined problem.
Founders should understand who experiences the problem, how often it occurs, what people currently do about it and why existing options are inadequate. This requires conversations with patients, clinicians, caregivers, purchasers and other relevant stakeholders.
In my work with women’s health founders and innovators, I often see teams that can explain their technology in great detail but have not yet defined the decision they want a customer, clinician or patient to make. That question is central to commercialisation.
The person using a product may not be the person paying for it or recommending it. A patient may use a device, a clinician may prescribe or recommend it, an insurer may determine reimbursement, and a health system may purchase it. Each participant evaluates value differently.
A product that feels useful to a consumer may not fit a clinical workflow. A tool that clinicians appreciate may be too expensive or difficult for patients to access. Understanding these differences early helps founders avoid building a technically impressive solution that is commercially difficult to adopt.
Define the evidence before development is complete
Evidence should be planned before major development decisions are finalised. Founders need to understand what claims they want to make and what evidence will be needed to support those claims.
A wellness product, a diagnostic tool and a medical device may face very different expectations. Intended use, target population, risk profile, technical performance and marketing claims all influence the development and regulatory pathway.
This does not mean every early-stage company needs a complete clinical programme immediately. It does mean the team should identify the questions that must eventually be answered:
- Does the product measure what it claims to measure?
- Does it work reliably across the intended population?
- Is it safe and comfortable to use?
- Does it improve a meaningful outcome?
- Can users understand and act on the information?
- Will clinicians, purchasers or investors consider the evidence credible?
Women are not a single homogeneous user group. Age, hormonal status, pregnancy history, ethnicity, body composition, disability, medication use and underlying health conditions may affect how a product performs.
The NIH expects sex to be considered as a biological variable in the design, analysis and reporting of relevant research.[1] The FDA also notes that participation of women in clinical trials helps ensure that medical products are studied in the population most likely to use them.[2]
The same principle applies to product development. A design based on narrow data may not perform equally well for the people it intends to serve.
This issue is not theoretical. FDA research has shown that melanin characteristics can affect signals detected by some biomedical optical devices, creating the potential for performance differences across skin pigmentation.[3] The broader lesson is that developers should identify relevant sources of variation early and test for them deliberately.
Treat manufacturing as part of innovation
Manufacturing is often considered after the design is complete. That can create avoidable delays, quality problems and expensive redesigns.
A women’s health product may need to account for skin sensitivity, body variation, comfort, hygiene, privacy, portability, cleaning, packaging and repeated use. These requirements affect materials, geometry, electronics, assembly methods, quality controls and cost structure.
Founders should ask early:
- Can the product be produced consistently at the required quality?
- Are the necessary materials and components available?
- Can the design be assembled and tested efficiently?
- What happens when production volumes increase?
- Does the target retail or reimbursement price support the manufacturing cost?
- Are alternative suppliers available if one becomes unavailable?
In founder discussions, manufacturing is often treated as a later operational issue. In practice, it can determine whether the business is viable. A design that works in a prototype may be impractical at scale because it depends on a difficult assembly process, an unavailable component or a cost structure that does not support the intended route to market.
For regulated products, development and manufacturing decisions also connect directly to quality-system expectations. FDA design-control guidance emphasises that device design must be controlled so specified requirements are met.[4]
Early engagement with engineering, quality and manufacturing specialists can reveal these issues before the company commits to tooling, inventory or a large development programme.
Protect the idea before disclosure
Intellectual-property strategy should be considered before founders begin extensive discussions with clinicians, manufacturers, investors, advisers and potential partners.
Those conversations can be valuable, but premature disclosure may affect patent rights in some jurisdictions. In the United States, an inventor-originated public disclosure may fall within a one-year grace period in certain circumstances, but the rules are jurisdiction-specific and should not be treated as universal protection.[5]
Founders should obtain appropriate legal advice before public presentations, conference posters, investor materials, website launches or detailed partner discussions.
The team should determine what is genuinely novel, what needs protection and which information can be shared safely. A patent is not automatically a business moat, and not every idea requires the same protection strategy. Depending on the product, relevant assets may include patents, trade secrets, software, data, designs, trademarks, know-how or a combination of these.
The more useful question is not simply, “Can we file a patent?” It is, “Which assets will make this company difficult to replace or copy as it grows?”
Build for adoption, not only technical performance
A product may perform well in testing and still fail in the real world if it is inconvenient, uncomfortable, expensive or difficult to understand.
Women’s health products often become part of intimate routines. That makes trust and usability central to adoption. The product may need to fit into a busy household, a clinical appointment, travel, work, exercise or caregiving responsibilities.
The FDA recommends human-factors and usability-engineering processes to help ensure that medical devices are safe and effective for their intended users, uses and environments.[6] Those principles are useful well before a company reaches a regulatory submission.
Privacy also needs to be designed into the product. Sensitive health information should be collected only when necessary, explained clearly and protected appropriately. Users should understand what is being measured, how the information is interpreted, who can access it and how long it is retained.
For digital-health and wearable products, more data does not always mean more value. Users need information that is understandable, relevant and connected to a reasonable next step. If a product creates anxiety without improving decision-making, engagement may decline even when the underlying technology is sophisticated.
Health-data obligations can also apply outside traditional healthcare settings. The Federal Trade Commission’s Health Breach Notification Rule covers certain developers of health applications and connected devices, including obligations relating to unauthorised disclosures of health information.[7]
Choose a realistic route to market
Commercialising women’s health innovation requires a clear path to the customer. Founders should decide whether they are building for direct-to-consumer sales, clinical channels, employers, health systems, pharmacies, insurers, licensing or a combination of routes.
Each route has different requirements.
Direct-to-consumer products may need strong education, brand trust, customer support and efficient fulfilment. Clinical products may require workflow integration, evidence, training, reimbursement analysis and procurement approval. Licensing may reduce a company’s manufacturing burden but may also affect control, margins and long-term strategy.
A useful commercialisation plan should identify:
- the first credible customer;
- the initial use case;
- the price or reimbursement logic;
- the decision-maker;
- the evidence required; and
- the milestones needed before adoption can occur.
Build the company around staged decisions
Founders do not need to solve every commercial question on the first day. They do need to sequence the questions properly.
A staged plan may begin with problem validation, followed by technical feasibility, intellectual-property review, regulatory assessment, prototype development, user testing, manufacturing analysis, evidence planning and market-entry preparation.
Each stage should produce information that supports the next investment decision. This helps founders avoid spending heavily before the most important uncertainties are understood. It also gives investors, partners and clinical stakeholders a clearer view of progress.
Women’s health innovation needs bold ideas, but it also needs disciplined execution. The strongest companies will connect patient needs, evidence, design, regulation, manufacturing, privacy and market access from the beginning.
Commercialisation is not the final step after innovation. It is the process that allows innovation to reach the people it was created to serve.
Author Bio
